CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
GAT Biosciences is developing GB-AF-004, an oral biologic for treating Inflammatory Bowel Diseases. This innovative treatment aims to address a significant unmet medical need for millions affected by chronic intestinal conditions.
GAT Biosciences (GATBIO) is a women-led Biotech SME targeting the exploitation of its proprietary GRTTM technology as a novel solution for the development and production of complex biologic drugs for biopharma and veterinary markets.
Specifically, we are developing a game-changer next generation of accessible and non-invasive (oral, topic, inhaled) biopharmaceuticals through proprietary and sustainable microalgae biofactories.Our first candidate for the biopharmaceutical Market, GB-AF-004, will…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
